Organovo Presents Data on Fully Cellular 3D Bioprinted Kidney Tissue

Inkbit

Share this Article

organovo-featBioprinting is in our future. No longer the stuff of sci-fi dreams, the technology is taking a true hold in today’s world — and even in the dictionary. By bringing 3D printing together with living cells to create viable organic structures, companies like San Diego, California-based Organovo (NYSE: ONVO) are changing the shape of medical technology.

Just this past November, Organovo announced that its 3D printed human liver tissue was commercially available, under the exVive3D name. The tissue, currently intended for use in pre-clinical drug trials, can significantly expedite the drug discovery process in the pharmaceutical industry, potentially bringing life-saving medicines to market that much sooner.

Organovo is at it again, just a few months later, today announcing data on the world’s first 3D bioprinted fully cellular kidney tissue, unveiled at the Experimental Biology conference in Boston.

“The first 3D bioprinted human kidney tissue hopes to help millions of people with kidney disease by providing a new model for medical research and drug testing,” Madeline Hirshan, Account Coordinator at Little Dog Communications, told 3DPrint.com in an email announcing Organovo’s development. “…Known as the silent disease, more than 25 million people in the United States are living with kidney disease, a growing epidemic (for context: 13M people are living with cancer and 29M people have diabetes).”

organovo bioprintingThe kidney tissue represents an important development in bioprinting, as Organovo proves its model for more than one type of human organ. The bioprinted human kidney tissue will also be utilized in pharmaceutical R&D, representing an enhancement on currently available models for testing which are not all that close to the actual human body. Furthermore, while current tissues are able to survive for only a few days in laboratory conditions, Organovo’s kidney tissue can last “at least two weeks.”

With so many people both in the US and the world at large suffering from kidney disease, this development could be big news. Three-dimensional, accurately replicated, fully cellular models will allow for testing of drug toxicity and efficacy and for the modeling of disease behavior in living tissue.

“Our bioprinted human kidney tissue represents a significant technical advance over the simple monolayer cell line cultures that predominate today,” said Organovo’s Chief Technology Officer and Executive Vice President of Research and Development, Dr. Sharon Presnell. “The histologic and functional features of the initial prototypes are compelling, and the in vitro durability of the system will likely enable the assessment of drug effects at chronic, physiologically relevant doses. Furthermore, the cellular complexity of the system will likely support mechanistic investigations into drug responses, including end points that have been difficult or impossible to assess in vitro, including tubular fibrosis and post-injury recovery.”

The data announced today is still preliminary, but ultimately the kidney tissue will be added to the company’s line of exVive3D tissues, along with the now-available exVive3D Liver. Both tissues are created using NovoGen, Organovo’s proprietary bioprinting platform. Currently, Organovo estimates that the kidney tissue will see its commercial release “in the latter half of calendar year 2016.”novogen bioprinter

“Kidney represents an ideal extension of Organovo’s capabilities to 3D bioprint organ tissues that can be tremendously useful in pharmaceutical research,” said Organovo’s Chairman and Chief Executive Officer, Keith Murphy. “The results released today admirably demonstrate a proof of concept that kidney is on the way to becoming another core commercial tissue for Organovo. The product that we intend to build from these initial results can be an excellent expansion for our core customers in toxicology, who regularly express to us an interest in having better solutions for the assessment of human kidney toxicity.”

While both tissues in the exVive3D line are or will be intended for drug trials, both represent critical stepping stones as science nears the now seemingly inevitable: bioprinting full human organs that are viable for transplant into live patients.

Let us know what you think about this latest bioprinting announcement in the Organovo Announces 3D Bioprinted Kidney Tissue forum thread over at 3DPB.com.

organovo home image

Share this Article


Recent News

BMW Creates Fully Automated Production Lines for 3D Printed Car Parts

Jabil Captures Carbon with New PK 5000 3D Printing Material



Categories

3D Design

3D Printed Art

3D Printed Food

3D Printed Guns


You May Also Like

EOS President of North America Discusses the Future of Metal Laser 3D Printing

EOS has been the long-established leader in laser sintering, representing the largest installed base in the market. However, as companies new and old attempt to push the segment, particularly in...

Sponsored

How Intelligent Automation and Networking of 3D Printing and Post-processing Increase Productivity

The market for Additive Manufacturing (AM) processes continues to grow and will even fivefold by 2030, according to SmarTech Analysis. More and more companies are taking a step towards the...

3D Printing Webinar and Event Roundup: May 1st, 2022

We’ve got another busy week of webinars and events ahead! 3D Systems has multiple offerings, while Stratasys continues its Experience Tour, Formlabs hosts The Digital Factory in Boston, and Nexa3D...

BASF Venture Replique Establishes 3D Printing Materials Network

Replique, part of the BASF venture builder, is establishing a 3D printing materials network to advance the production of 3D printed parts. This partner network of authorized material vendors is...